BRANFORD, Conn.--(BUSINESS WIRE)--454 Life Sciences, a Roche Company, announced today that it has entered an exclusive partnership with DNA Electronics for the development of a low-cost, high-throughput DNA sequencing system. As part of the agreement, Roche has signed a non-exclusive license for relevant IP from DNA Electronics’ proprietary semiconductor technology portfolio, which enables sensitive detection of nucleotide incorporation during sequencing. The technology will build on 454 Life Sciences’ current pyrosequencing-based sequencing platforms by enabling a seamless evolution from optical detection to inexpensive, highly scalable electrochemical detection. The collaboration leverages 454 Life Sciences’ long read sequencing chemistry with DNA Electronics’ unique knowledge of semiconductor design and expertise in pH-mediated detection of nucleotide insertions, to produce a long read, high density sequencing platform. Financial details of the agreement were not disclosed.
